STAA Market Analysis

Overview

Fundamentals

P/E ratioForward 97.09
EPS (TTM)$-1.62-10.5% YoY
Profit margin-33.6%HEALTHCARE
Market cap$1.35BSmall cap

Wall Street coverage

$21.11median target· current $45.98 (-54.1%)11 analysts

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

Valuation

Forward P/E
97.09
PEG ratio
0.76
P/B
3.91
P/S (TTM)
5.62
EV/EBITDA
28.07

Profitability & growth

ROE (TTM)
-21.7%
Operating margin
-18.9%
Revenue growth YoY
18.1%
Dividend yield
Beta
1.04
Last earnings
Feb 25, 2026 · Estimate $0.15 · Reported $0.01
Analyst estimate. Actual results often differ.

Ratios are point-in-time. Historical metrics — no guarantees about what comes next.

News & Sentiment

Page 1 of 3 · 50 total

Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.

About STAAR Surgical Company

STAAR Surgical Company designs, develops, manufactures, markets and sells implantable eye lenses and supplemental delivery systems for placing the lenses in the eye. The company is headquartered in Lake Forest, California.

Classification

Exchange
NASDAQ
Country
USA
Currency
USD

Company profile

HQ
25510 COMMERCENTRE DRIVE, LAKE FOREST, CA
Fiscal year end
December
Latest quarter
Dec 31, 2025
Market cap$1.35B
Shares outstanding$49.5M
52W high$30.81
52W low$15.59

Educational content · Not investment advice or recommendations

We're educators, not advisors. Your decisions are your own. Disclaimer